ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2409724122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Liangzhan Sun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, CD24 Antigen, RNA-Binding Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), GDSTC | Natural Science Foundation of Guangdong Province (), | Natural Science Foundation of Shenzhen Municipality (Shenzhen Natural Science Foundation).
Abstract (Originalsprache)
ADAR is highly expressed and correlated with poor prognosis in hepatocellular carcinoma (HCC), yet the role of its constitutive isoform ADARp110 in tumorigenesis remains elusive. We investigated the role of ADARp110 in HCC and underlying mechanisms using clinical samples, a hepatocyte-specific Adarp110 knock-in mouse model, and engineered cell lines. ADARp110 is overexpressed and associated with poor survival in both human and mouse HCC. It creates an immunosuppressive microenvironment by inhibiting total immune cells, particularly cytotoxic GZMB + CD8 + T cells infiltration, while augmenting Treg cells, MDSCs, and exhausted CD8 + T cells ratios. Mechanistically, ADARp110 interacts with SNRPD3 and RNPS1 to stabilize CD24 mRNA by inhibiting STAU1-mediated mRNA decay. CD24 protects HCC cells from two indispensable mechanisms: macrophage phagocytosis and oxidative stress. Genetic knockdown or monoclonal antibody treatment of CD24 inhibits ADARp110-overexpressing tumor growth. Our findings unveil different mechanisms for ADARp110 modulation of tumor immune microenvironment and identify CD24 as a promising therapeutic target for HCCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China.
- Department of Clinical Oncology, The University of Hong Kong, Hong Kong 999077, China.
- State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong 999077, China.
- Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen 518067, China.
- Peking University Shenzhen Graduate School, Peking University, Shenzhen 518055, China.
- Department of Oncology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China.
ORCID-Profile: Xin-Yuan Guan, Yan Li
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- GDSTC | Natural Science Foundation of Guangdong Province ()
- | Natural Science Foundation of Shenzhen Municipality (Shenzhen Natural Science Foundation)
- 深圳市科技创新委员会 | Natural Science Foundation of Shenzhen Municipality
Zitieren
APA
Sun, L., Hu, P., Yang, H., Ren, J., Hu, R., Wu, S., Wang, Y., Du, Y., Zheng, J., Wang, F., Gao, H., Yan, J., Yuan, Y. F., Guan, X. Y., Xiao, J., & Li, Y. (2025). ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2409724122
Vancouver
Sun L, Hu P, Yang H, Ren J, Hu R, Wu S, et al. ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2409724122
BibTeX
@article{Sun2025,
author = {Sun, Liangzhan and Hu, Pengchao and Yang, Hui and Ren, Jun and Hu, Rong and Wu, Shasha and Wang, Yanchen and Du, Yuyang and Zheng, Jingyi and Wang, Fenfen and Gao, Han and Yan, Jingsong and Yuan, Yun-Fei and Guan, Xin-Yuan and Xiao, Jia and Li, Yan},
title = {ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2409724122}
}
EUVIMED